SENS

Senseonics Holdings

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/14/26

Business Summary

Senseonics develops and commercializes implantable continuous glucose monitoring systems designed for long-term diabetes management. The company generates revenue by selling its monitoring devices and related components to patients and healthcare providers. Its potential moat lies in differentiated implantable sensor technology that extends sensor life compared to traditional wearable systems. However, until it can translate product differentiation into sustained positive margins and returns on capital, its moat remains technological rather than financial.

 


Analyze SENS on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$279

Forward P/E

-

PEG

-

PRICE TO SALES

7.9

PRICE TO BOOK

4.6

EV / EBITDA

-3.6

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.66

Next Year EPS Growth Estimate

-$2.63

Next Year Revenue Growth Estimate

60.00%

Return on Equity (ROE)

-113.20%

FREE CASH FLOW

Operating Margin

-193.80%

Debt-to-Equity

0.7

Piotroski F-Score

5

Altman Z-Score

-9.3

Return on Invested Capital (ROIC)

-93.10%

Current Ratio

4.8

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze SENS on TradingView

Gainseekers Quantitative Analysis

Summary

This is a highly distressed, speculative medical device name masquerading as a growth story. With no P/E, no Forward P/E, no PEG, and an Altman Z-Score of -9.3, the balance sheet signals extreme financial fragility and elevated bankruptcy risk. EPS sits at -3.6 with next year still projected at -1.66, while operating margin is a catastrophic -113.20% and ROIC is -93.10%, meaning capital is being destroyed at scale. A Price/Sales of 7.9 and Price/Book of 4.6 are aggressive multiples for a company with negative profitability and deteriorating fundamentals. This is not a misunderstood compounder — it is a capital-intensive turnaround with severe financial stress and no valuation anchor.

AI Exposure / Tech Reliance

As a medical devices company, it operates in a sector increasingly influenced by AI-driven diagnostics, remote monitoring, and data analytics. Healthcare hardware tied to continuous monitoring can benefit from AI-enhanced interpretation and patient management systems. However, its financial weakness limits its ability to aggressively invest in or capitalize on these technological shifts without further capital dilution.

The Bull Case

The only rational bull case hinges on optionality and survivability rather than current performance. A Piotroski F-Score of 5 indicates middling financial stability — not strong, but not completely broken — and a Current Ratio of 4.8 suggests short-term liquidity is currently adequate. Institutional ownership at 18.70% implies some professional capital remains engaged, potentially betting on operational inflection ahead of the projected EPS improvement from -3.6 to -1.66. If operating leverage improves materially, the high 7.9 Price/Sales multiple could compress quickly through revenue scaling rather than multiple contraction. For aggressive GARP investors, this is a turnaround speculation where even modest margin normalization from -113.20% could create asymmetric upside.

The Bear Case

The bear case is overwhelming. A Debt/Equity ratio of -193.80% combined with a -9.3 Altman Z-Score screams structural balance sheet stress, while ROIC of -93.10% confirms that management is destroying shareholder value. Operating margin at -113.20% means the core business model is not economically viable at current scale, and there is no Forward P/E or PEG to support a growth narrative. Price/Sales at 7.9 and Price/Book at 4.6 are unjustifiable for a company with negative earnings, negative returns, and projected continued losses. With Sales Growth Next Year listed at -$2.63 and no dividend support, investors are effectively underwriting dilution risk and solvency risk simultaneously.

Market Sentiment & Smart Money

Short Interest %

11.90%

Analyst Consensus

2.11

Average Analyst Price Target

$18.70

Institutional Ownership %

16.00%

1-Year Beta

2.2

Insider Buying % (6 Mo)

9.60%%

Distance to 52-Week High

42.40%

Distance to 52-Week Low

127.20%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.